Stock Titan Trading tools for traders and investors.

-

01:42:30 AM

Last REGN Stock Market News

REGN - Regeneron Pharmaceuticals, Inc.

02/26/21 6:46 AM

Nasdaq : REGN

EMA Issues Advice on Regeneron's Antibody Cocktail (casirivimab with imdevimab) for Certain COVID-19 Patients

EU member states can utilize the positive CHMP opinion when making national decisions about use of the antibody cocktail, prior to a potential future EMA market authorizationRegeneron has collaborated with Roche to develop and manufacture the antibody

RHEA-AI

positive

02/25/21 7:00 AM

Nasdaq : REGN

Independent Data Monitoring Committee Finds Clear Efficacy for REGEN-COV(TM) (casirivimab with imdevimab) in Phase 3 COVID-19 Outpatient Outcomes Trial

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced changes to the Phase 3 trial assessing investigational REGEN-COV(TM) (casirivimab with imdevimab) in non-hospitalized patients ("outpatients") with COVID-19, following recommendations from the

RHEA-AI

neutral

02/22/21 1:00 PM

Nasdaq : REGN

FDA Approves Libtayo(R) (cemiplimab-rwlc) Monotherapy for Patients with First-line Advanced Non-small Cell Lung Cancer with PD-L1 Expression of >=50%

Libtayo was superior in extending overall survival compared to chemotherapy in a pivotal trial that allowed for certain disease characteristics frequently underrepresented in advanced NSCLC trialsThis is the third approval for Libtayo in the

RHEA-AI

positive

02/12/21 4:15 PM

Nasdaq : REGN

Regeneron Announces Investor Conference Presentations

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:SVB Leerink 10th Annual Global Healthcare Conference at 10:40 a.m. EST on Wednesday, February 24, 2021 Cowen 41st Annual Health Care Conference at 9:10

RHEA-AI

neutral

02/12/21 1:00 AM

Nasdaq : REGN

The Lancet Publishes Libtayo(R) (cemiplimab) Data Showing Extended Overall Survival in Patients with First-line Advanced Non-small Cell Lung Cancer with PD-L1 Expression of >=50%

Libtayo was superior in extending overall survival compared to chemotherapy even with a high crossover rateData are the basis for multiple ongoing regulatory submissions, including in the U.S. and European UnionRegeneron Pharmaceuticals,

RHEA-AI

very positive

02/11/21 5:04 PM

Nasdaq : REGN

U.S. Federal Circuit Court of Appeals Rules in Favor of Regeneron and Sanofi in Praluent(R) (alirocumab) Patent Litigation

Upholds decision by U.S. District Court to invalidate Amgen's patent claims directed to PCSK9 antibodiesRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the United States Court of Appeals for the Federal Circuit upheld the decision

RHEA-AI

negative

02/11/21 2:00 PM

Nasdaq : REGN

FDA Approves First-in-class Evkeeza(TM) (evinacumab-dgnb) for Patients with Ultra-rare Inherited Form of High Cholesterol

Homozygous familial hypercholesterolemia ( HoFH) is an ultra-rare inherited condition that affects approximately 1,300 patients in the U.S. and is characterized by extremely high low-density lipoprotein cholesterol ( LDL-C)In pivotal Phase 3 HoFH

RHEA-AI

positive

02/09/21 5:22 PM

Nasdaq : REGN

FDA Approves Libtayo(R) (cemiplimab-rwlc) as First Immunotherapy Indicated for Patients with Advanced Basal Cell Carcinoma

Following Priority Review Libtayo receives full approval in locally advanced basal cell carcinoma (BCC) and accelerated approval in metastatic BCCLibtayo now approved for patients with advanced stages of the two most common skin cancers in

RHEA-AI

positive

02/05/21 6:30 AM

Nasdaq : REGN

Regeneron Reports Fourth Quarter and Full Year 2020 Financial and Operating Results

Fourth quarter 2020 revenues increased 30% to $2.42 billion versus fourth quarter 2019 (4) Fourth quarter 2020 EYLEA (R) U.S. net sales increased 10% to $1.34 billion versus fourth quarter 2019 and full year 2020 EYLEA U.S. net sales increased 7% versus

RHEA-AI

neutral

02/01/21 9:59 AM

Nasdaq : REGN

New Dupixent(R) (dupilumab) Data Showcasing Improvements Across Four Type 2 Inflammatory Diseases to be Presented at 2021 AAAAI Annual Meeting

Improvements were noted across key disease measures in certain patients with asthma, atopic dermatitis, eosinophilic esophagitis and chronic rhinosinusitis with nasal polyposisNew analyses build on a robust body of evidence reinforcing the

RHEA-AI

neutral

1 2 3 4 5 6 7 Next